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existence and strength of negative feed-
back mechanisms, set the threshold of
AKT activation in a given setting. The
cellular levels of FKBP51 appear to be
another major factor in dictating this
threshold. As for downstream signaling,
is there a specific target of AKT that is
particularly dependent on the elevated
levels of AKT activity provided by
increased S473 phosphorylation and that
dictates the development of chemoresist-
ance? Although there are many candidate
pathways, previous studies on mouse
tumor models suggest that mTOR
complex 1 (mTORC1) activation can drive
chemoresistance in response to in-
creased AKT signaling (Wendel et al.,
2004). Finally, in addition to the mecha-
nistic questions above, it will be important
to determine whether FKBP51 levels
provide a clinical biomarker predicting
whether a given tumor should be targeted
with chemotherapeutics alone or in
combination with emerging inhibitors of
the PI3K-AKT pathway.
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Paragangliomas have been linked to mutations affecting the succinate dehydrogenase complex. In a recent
issue of Science, Rutter and coworkers showed that SDH5 is required for the flavination of SDHA, which is
necessary for SDH assembly and function. Moreover, they detected SDH5 mutations in a large kindred
with familial paraganglioma.Otto Warburg observed decades ago that
cancer cells display high rates of glycol-
ysis, with the subsequent conversion of
pyruvate to lactate, even when oxygen is
available for the far more efficient pro-
duction of ATP via the conversion of pyru-
vate to acetyl-CoA and subsequent ox-
idation via the Krebs cycle. How cancer
cells establish this pattern of ‘‘aerobic
glycolysis’’ is becoming clearer. For ex-
ample, many oncogenic mutations acti-
vate mTOR, which in turn induces HIF1a.
HIF1a transcriptionally activates many
genes that promote glucose uptake and
glycolysis. HIF1a also induces PDK1,
which phosphorylates pyruvate dehydro-
genase and thereby inhibits the entry of
pyruvate into the Krebs cycle (Kroemer180 Cancer Cell 16, September 8, 2009 ª2and Pouyssegur, 2008). Finally, HIF1a
induces BNIP3, which promotes mito-
chondrial autophagy, and transcription-
ally suppresses genes required for mito-
chondrial biosynthesis (Kroemer and
Pouyssegur, 2008; Zhang et al., 2008).
Another insight came with the recent
discovery that cancer cells preferentially
express the M2 isoform of pyruvate
kinase, which is inhibited by the increased
tyrosine kinase signaling typical of many
cancer cells, leading to decreased oxida-
tive phosphorylation and enhanced lac-
tate production (Vander Heiden et al.,
2009).
‘‘Why,’’ as opposed to ‘‘how,’’ cancers
resort to aerobic glycolysis is less clear,
however. One possibility stems from the009 Elsevier Inc.observation that unicellular organisms re-
plicate their DNA and undergo cell divi-
sion while engaged in reductive, rather
than oxidative, metabolism, possibly to
limit damage from endogenous reactive
oxygen species (ROS) (Tu and McKnight,
2007). Perhaps aspects of this ancient
coupling of metabolism to proliferation
are still ‘‘hard-wired’’ in metazoans, in
which case the shift to aerobic glycolysis
might be more conducive for cell prolifer-
ation. It has also been proposed that
glycolysis enhances the production of
the building blocks necessary for anabo-
lism (Kroemer and Pouyssegur, 2008;
Vander Heiden et al., 2009). Nonetheless,
Warburg’s contention that altered metab-
olism caused cancer was gradually
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caused by mutations, some of which
lead, as a consequence, to altered
metabolism.
Interest in Warburg’s observations has
been rekindled, however, with the recent
discovery that the Krebs cycle compo-
nents succinate dehydrogenase (SDH)
and fumarate hydratase (FH) are targets
of germline mutations that cause heredi-
tary paragangliomas (PGL) and papillary
renal carcinomas, respectively (Vander
Heiden et al., 2009). Moreover, somatic
mutations affecting isocitrate dehydroge-
nase 1 and 2, which normally convert iso-
citrate to the Krebs cycle-intermediate
a-ketoglutarate, have been described in
some brain tumors (Vander Heiden et al.,
2009). These genetic studies prove that
metabolic deregulation can cause cancer.
SDH is a heteroligomer containing the
subunits SDH A, B, C, and D and muta-
tions of subunits B, C, and D have been
linked to hereditary paragangliomas
(PGL4, PGL3, and PGL1 syndromes, re-
spectively). Rutter and coworkers, appre-
ciating that many mitochondrial proteins
are relatively uncharacterized, honed in
on an evolutionarily conserved yeast mi-
tochondrial protein, which they now call
SDH5 (Hao et al., 2009). They found that
SDH5 binds to SDHA (SDH1 in yeast)
and, at least indirectly, promotes its flavi-
nation. Flavination of SDH1, for reasons
that are not yet clear, is required for SDH
complex assembly and function. Loss of
SDH5 in yeast decreases the abundance
of the other SDH components, probably
caused by enhanced degradation as
a result of altered SDH complex forma-
tion. SDH converts succinate to fumarate
and also participates in the electron trans-
port chain. Both of these activities are
diminished in yeast lacking SDH5 and
can be complemented with the human
SDH5 ortholog (hSDH5). Some familial
paraganglioma families (PGL2) display
linkage to 11q13.1, which is the location
for hSDH5. Rutter and coworkers identi-
fied a nonsynonomous hSDH5 variant in
one such family and confirmed that it
was defective with respect to SDH1 flavi-
nation and restoration of SDH activity
when introduced into Dsdh5 yeast,
implying that SDH5 mutations, like muta-
tions affecting SDH subunits B, C, and,
D, cause paraganglioma by abrogating
SDH activity.
How might loss of SDH or FH cause
cancer? Twononmutually exclusivemech-
Figure 1. Potential Links Between Krebs Cycle and 2-Oxoglutarate-dependent Dioxygenase
Activity
For simplicity, individual subunits of multimeric complexes are not shown. Increased activity (red triangle
in meter) of certain 2-oxoglutarate-dependent dioxygenases, such as the proapoptotic prolyl hydroxylase
PHD3 (EglN3), is envisioned to suppress tumor formation. Mutations affecting SDH or FH promote the
accumulation of succinate and fumarate, respectively, which suppress the catalytic activity of 2-oxoglu-
tarate-dependent dioxygenases.Cancer Cell 16,anisms have been put forth. Many 2-oxo-
glutarate-dependent enzymes have now
been identified, including the PHD (also
called EglN) prolyl hydroxylases that
promote HIFa polyubiquitinylation and
degradation and the FIH1 asparaginyl
hydroxylase that inhibits HIFa transacti-
vation function. The catalytic activity of
these enzymes is coupled to the decar-
boxylation of 2-oxoglutarate (also called
a-ketoglutarate) to succinate and is in-
hibited in the presence of excess suc-
cinate or the closely related molecule
fumarate, such as occurs upon SDH and
FH inactivation, respectively (Figure 1).
Moreover, loss of SDH or FH activity has
been reported to increase mitochondrial
ROS production, which also inhibits diox-
ygenase function (Guzy et al., 2008;
Sudarshan et al., 2009). A caveat, how-
ever, is that not all investigators have de-
tected an increase in ROS production in
SDH-defective mammalian cells (Cervera
et al., 2008; Lee et al., 2005; Selak et al.,
2006). Nonetheless, it is clear that SDH
and FH mutations activate HIF, indicating
that SDH and FH mutations compromise
the function of the PHD dioxygenases,
leading to a state of ‘‘pseudohypoxia’’
(Dahia et al., 2005; Isaacs et al., 2005).
HIF activation, for the reasons stated
above, would enhance glycolysis while
potentially further decreasing flux through
the Krebs cycle. Moreover, HIF can
promote the transformation of certain
cell types, as best demonstrated by the
critical role of HIF2a in clear cell renal
carcinomas linked to loss of the von
Hippel-Lindau protein. It is intriguing
that FH mutations cause kidney cancer
(albeit with papillary rather than clear cell
histology) and that SDH mutations have
also been detected in kidney cancer, sug-
gesting that renal epithelial cells might be
particularly susceptible to HIF-induced
transformation.
Many other 2-oxoglutarate-dependent
dioxygenases are also involved in cancer-
relevant processes such as extracellular
matrix formation (for example, the col-
lagen prolyl and lysyl hydroxylases), RNA
splicing (Jmjd6), and chromatin structure
(for example, the JmjC-containing histone
demethylases). Such proteins might also
couple Krebs cycle metabolism to trans-
formation. Complicating matters further,
many of these proteins are encoded by
HIF-responsive genes, presumably to
compensate for diminished availability ofSeptember 8, 2009 ª2009 Elsevier Inc. 181
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oxic conditions. Thus, these enzymes
form an oxygen and metabolism-respon-
sive network.
Why are SDH mutations linked to a
small subset of tumors (primarily para-
gangliomas) rather than a wide variety of
tumors? One hypothesis relates to the
embryological origins of paragangliomas,
which are tumors of the sympathetic ner-
vous system. During embryological de-
velopment, an excess number of neuro-
blasts with the potential to become
sympathetic neurons are generated.
These cells then compete with one an-
other for growth factors such as NGF,
with the losers undergoing apoptosis.
PHD3 (EglN3) appears to be both neces-
sary and sufficient for apoptosis in this
setting, which appears to be largely HIF
independent (Lee et al., 2005). Loss of
SDH activity, for reasons outlined above,
blunts PHD3-induced apoptosis. Like-
wise, the other genes linked to familial
paraganglioma (including NF1, c-Ret, and
VHL) ultimately impact upon this pathway,
suggesting that paragangliomas arise be-
cause certain neuronal precursors elude
development culling (Lee et al., 2005).
This model would explain why somatic182 Cancer Cell 16, September 8, 2009 ª20SDH mutations are relatively rare in spo-
radic paragangliomas unless accompa-
nied by a previously unsuspected, germ-
line, SDH mutation (similar rules apply to
NF1, c-Ret, and VHL in this setting).
The discovery of SDH, FH, and IDH
mutations has renewed hope that can-
cer cell metabolism can be exploited ther-
apeutically. Some progress has been
made toward identifying targets that are
particularly important for the survival of
highly glycolytic tumor cells. In addition,
2-oxoglutarate-dependent dioxygenases
can be reactivated with drug-like mole-
cules (Kroemer and Pouyssegur, 2008).
The development of a successful cancer
therapeutic along these lines would be
further testimony to the vision of Otto
Warburg.
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